

Antibiotic Susceptibility of *Escherichia coli* ATCC® BAA-3303™

Antimicrobial	MIC ^a	Interpretation ^b	Antimicrobial	MIC	Interpretation
Amikacin	8	S	Cefuroxime	≥64	R
Amoxicillin / Clavulanic Acid	≥32	R	Cefuroxime Axetil	≥64	R
Ampicillin	≥32	R	Ciprofloxacin	≥4	R
Ampicillin / Sulbactam	≥32	R	Ertapenem	≥8	R
Aztreonam	≥64	R	Gentamicin	≥16	R
Cefalotin	≥64	R	Imipenem	2	S
Cefazolin	≥64	R	Levofloxacin	≥8	R
Cefepime	8	S	Meropenem	4	S
Cefotaxime	≥64	R	Moxifloxacin	≥8	R
Cefotetan	16	S	Nalidixic Acid	≥32	R
Cefoxitin	16	I	Nitrofurantoin	32	S
Cefpodoxime	≥8	R	Piperacillin / Tazobactam	≥128	R
Ceftazidime	16	I	Tetracycline	≤1	S
Ceftazidime / Avibactam	0.5	S	Tigecycline	≤0.5	S
Ceftolozane / Tazobactam	≥32	R	Tobramycin	≥16	R
Ceftriaxone	≥64	R	Trimethoprim / Sulfamethoxazole	≤20	S

^a Antibiotic susceptibility was obtained using a Vitek2 AST-GN69 and AST-XN09 cards.

^b Parameter set: MIC Interpretation Guideline: CLSI M100-S27 (2017)
Therapeutic Interpretation Guideline: Natural Resistance

Example:**Antibiotic Susceptibility of *Pseudomonas aeruginosa* ATCC® BAA-2112™**

Antimicrobial	MIC ^a	Interpretation ^b	Antimicrobial	MIC	Interpretation
Amikacin	8	S	Gentamicin	4	S
Amoxicillin / Clavulanic Acid	≥32	R	Imipenem	≤1	S
Ampicillin	≥32	R	Levofloxacin	1	S
Ertapenem	N/A	N/A	Nitrofurantoin	≥512	R
Cefalotin	≥64	R	Norfloxacin	2	S
Cefazolin	≥64	R	Piperacillin / Tazobactam	8	S
Cefepime	4	S	Tetracycline	≥16	R
Cefotaxime	32	R	Tigecycline	≥8	R
Cefoxitin	≥64	R	Tobramycin	≤1	S
Cefpodoxime	≥8	R	Trimethoprim / Sulfamethoxazole	80	R
Ceftazidime	4	S			
Ceftriaxone	16	R			
Cefuroxime	≥64	R			
Ciprofloxacin	≤0.25	S			
Cefuroxime Axetil	≥64	R			

^a Antibiotic susceptibility was obtained using a Vitek2 AST-GN22 and AST-GN23 cards.

^b Parameter set: MIC Interpretation Guideline: CLSI M100-S16 (2006)
Therapeutic Interpretation Guideline: Natural Resistance